Claims
- 1. A sustained release solid dosage form comprising the following components:
a) a uniform admixture of:
(i) an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure: 20 wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; and
(ii) a binder; and b) a hydroxypropylmethyl cellulose.
- 2. The solid dosage form of claim 1, wherein the solid dosage form is a tablet.
- 3. The solid dosage form of claim 1 or 2, wherein the uniform admixture of component a) further comprises a filler.
- 4. The solid dosage form of claim 3, wherein the filler comprises a microcrystalline cellulose.
- 5. The solid dosage form of claim 1 or 2, wherein the hydroxypropylmethyl cellulose comprises 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxyproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve, has an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C., and has a pH in the range 5.5-8.0.
- 6. The solid dosage form of claim 5, wherein at least 90% of the hydroxypropylmethyl cellulose passes through a No. 100 US standard sieve.
- 7. The solid dosage form of claim 1 or 2, further comprising as additional components a filler, a lubricant and a flow agent.
- 8. The solid dosage form of claim 1 or 2, wherein the binder of component a)(ii) comprises hydroxypropyl cellulose.
- 9. The solid dosage form of claim 1 or 2, further comprising a different hydroxypropylmethyl cellulose as a component.
- 10. The solid dosage form of claim 3, further comprising as additional components a filler, a lubricant and a flow agent.
- 11. The solid dosage form of claim 10, further comprising a different hydroxypropylmethyl cellulose as a component.
- 12. The solid dosage form of claim 9 or 11, wherein the different hydroxypropylmethyl cellulose comprises 19-24% by weight methoxyl substituent, 7-9% by weight hydroxypropoxyl substituent, has an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C., has a pH in the range 5.5-8.0 and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve.
- 13. The solid dosage form of claim 12, wherein at least 90% of the hydroxypropylmethyl cellulose passes through a No. 100 US standard sieve.
- 14. The solid dosage form of claim 7, wherein
the filler comprises a microcrystalline cellulose, anhydrous dicalcium phosphate, lactose, methylcellulose, carboxymethylcellulose, calcium carbonate, calcium sulfate kaolin, sodium chloride, powdered cellulose, sucrose, mannitol or a combination of two or more of the foregoing; the lubricant comprises magnesium stearate, sodium stearyl fumarate, hydrogenated castor oil, hydrogenated soybean oil, polyethylene glycol or a combination of two or more of the foregoing; and the flow agent comprises a colloidal fumed silica, or colloidal silicon dioxide.
- 15. The solid dosage form of claim 14 wherein
the filler comprises a microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing; the lubricant comprises magnesium stearate, sodium stearyl fumarate or a combination thereof; and the flow agent comprises a colloidal fumed silica.
- 16. The solid dosage form of claim 1 or 2 wherein the active ingredient is a compound having the structure:
- 17. The solid dosage form of claim 16, wherein the active ingredient is N-(2-Propylpentanoyl)glycinamide.
- 18. A sustained release solid dosage form comprising the following components:
a) a uniform admixture of:
(i) N-(2-Propylpentanoyl)glycinamide; and (ii) a binder; b) a hydroxypropylmethyl cellulose; and c) a different hydroxypropylmethyl cellulose.
- 19. The solid dosage form of claim 18, wherein the solid dosage form is a tablet.
- 20. The solid dosage form of claim 18 or 19, comprising a filler, a lubricant and a flow agent as additional components and wherein the uniform admixture of component a) further comprises a filler.
- 21. The solid dosage form of claim 20, wherein
the binder of component a)(ii) comprises hydroxypropyl cellulose; the filler of component a) comprises a microcrystalline cellulose; the hydroxypropylmethyl cellulose of component b) has an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; the hydroxypropylmethyl cellulose of component c) has an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.; the filler component comprises a microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing; the lubricant component comprises magnesium stearate, sodium stearyl fumarate or a combination thereof; and the flow agent component comprises a colloidal fumed silica.
- 22. The solid dosage form of claim 21, comprising the following components:
a) a uniform admixture of:
(i) from 50 mg/solid dosage form to 1000 mg/solid dosage form of N-(2-propylpentanoyl) glycinamide, (ii) from 1 mg/solid dosage form to 100 mg/solid dosage form hydroxypropyl cellulose; and (iii) from 1 mg/solid dosage form to 200 mg/solid dosage form microcrystalline cellulose; b) from 10 mg/solid dosage form to 300 mg/solid dosage form of hydroxypropylmethyl cellulose having 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve; c) from 10 mg/solid dosage form to 300 mg/solid dosage form of a different hydroxypropylmethyl cellulose having 19%-24% by weight methoxyl substituent, 7%-12% hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve; d) from 1 mg/solid dosage form to 300 mg/solid dosage form microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing; e) from 0.1 mg/solid dosage form to 20 mg/solid dosage form of magnesium stearate, sodium stearyl fumarate or a combination thereof; and f) from 0.1 mg/solid dosage form to 15 mg/solid dosage form a colloidal fumed silica.
- 23. The solid dosage form of claim 21, comprising the following components:
a) a uniform admixture of:
(i) from 500 mg/solid dosage form to 850 mg/solid dosage form of N-(2-propylpentanoyl) glycinamide, (ii) from 25 mg/solid dosage form to 75 mg/solid dosage form hydroxypropyl cellulose; and (iii) from 50 mg/solid dosage form to 150 mg/solid dosage form microcrystalline cellulose; b) from 100 mg/solid dosage form to 300 mg/solid dosage form of hydroxypropylmethyl cellulose having 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve; c) from 20 mg/solid dosage form to 150 mg/solid dosage form of a different hydroxypropylmethyl cellulose having 19%-24% by weight methoxyl substituent, 7%-12% hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve; d) from 20 mg/solid dosage form to 100 mg/solid dosage form microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing; e) from 2 mg/solid dosage form to 20 mg/solid dosage form of magnesium stearate, sodium stearyl fumarate or a combination thereof; and f) from 0.5 mg/solid dosage form to 5 mg/solid dosage form a colloidal fumed silica, per 1 gram solid dosage form.
- 24. The solid dosage form of any one of claims 22 or 23, wherein at least 90% of the hydroxypropylmethyl cellulose of component b), of component c), or of both component b) and c) passes through a No. 100 US standard sieve.
- 25. The solid dosage form of claim 23, wherein
the hydroxypropylmethyl cellulose of component b) has an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; and the hydroxypropylmethyl cellulose of component c) has an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.
- 26. The solid dosage form of claim 23, comprising the following components:
a) a uniform admixture of
(i) 500 mg/solid dosage form N-(2-Propylpentanoyl)glycinamide, (ii) 50 mg/solid dosage form hydroxypropyl cellulose; and (iii) 100 mg/solid dosage form microcrystalline cellulose; b) 150 mg/solid dosage form of hydroxypropylmethyl cellulose having 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve; c) 60 mg/solid dosage form of a different hydroxypropylmethyl cellulose having 19%-24% by weight methoxyl substituent, 7%-12% hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve; d) 20 mg/solid dosage form lactose; e) 4.5 mg/solid dosage form magnesium stearate; and f) 1 mg/solid dosage form colloidal fumed silica.
- 27. The solid dosage form of claim 26, wherein at least 90% of the hydroxypropylmethyl cellulose of component b), of component c), or of both component b) and c) passes through a No. 100 US standard sieve.
- 28. The solid dosage form of claim 26, wherein
the hydroxypropylmethyl cellulose of component b) has an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; and the hydroxypropylmethyl cellulose of component c) has an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.
- 29. A hard compressed tablet comprising a uniform admixture of the following components:
a) N-(2-Propylpentanoyl)glycinamide; b) a hydroxypropylmethyl cellulose; and c) a different hydroxypropylmethyl cellulose.
- 30. The tablet of claim 29, wherein
the hydroxypropylmethyl cellulose component b) has 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve; and the hydroxypropylmethyl cellulose component c) has 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve.
- 31. The tablet of any one of claims 29 or 30, wherein at least 90% of the hydroxypropylmethyl cellulose of component b), of component c), or of both component b) and c) passes through a No. 100 US standard sieve.
- 32. The tablet of claim 30, wherein
the hydroxypropylmethyl cellulose component b) has an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; and the hydroxypropylmethyl cellulose component c) has an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.
- 33. The tablet of claim 29, further comprising a filler, lubricant and flow agent as additional components.
- 34. The tablet of claim 33, wherein
the filler comprises a microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing; the lubricant comprises sodium stearyl fumarate; and the flow agent comprises a colloidal fumed silica.
- 35. The tablet of claim 34, comprising a uniform admixture of the following components:
a) from 100 mg/tablet to 1000 mg/tablet N-(2-Propylpentanoyl)glycinamide; b) from 10 mg/tablet to 300 mg/tablet of hydroxypropylmethyl cellulose with an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; c) from 10 mg/tablet to 300 mg/tablet of hydroxypropylmethyl cellulose with an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.; d) from 1 mg/tablet to 300 mg/tablet a microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing; e) from 0.1 mg/tablet to 20 mg/tablet sodium stearyl fumarate; and f) from 0.1 mg/tablet to 15 mg/tablet a colloidal fumed silica.
- 36. The tablet of claim 34, comprising a uniform admixture of the following components:
a) from 400 mg/tablet to 1000 mg/tablet N-(2-Propylpentanoyl)glycinamide; b) from 100 mg/tablet to 300 mg/tablet of hydroxypropylmethyl cellulose with an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; c) from 20 mg/tablet to 150 mg/tablet of hydroxypropylmethyl cellulose with an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.; d) from 10 mg/tablet to 60 mg/tablet a microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing; e) from 2 mg/tablet to 20 mg/tablet sodium stearyl fumarate; and f) from 5 mg/tablet to 15 mg/tablet a colloidal fumed silica, per 1 gram tablet.
- 37. The tablet of claim 36, comprising a uniform admixture of the following components:
a) 500 mg/tablet N-(2-Propylpentanoyl)glycinamide; b) 150 mg/tablet of hydroxypropylmethyl cellulose with an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; c) 60 mg/tablet of hydroxypropylmethyl cellulose with an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.; d) 20 mg/tablet lactose; e) 10 mg/tablet sodium stearyl fumarate; and f) 10 mg/tablet colloidal fumed silica.
- 38. A composition in granulate form comprising a uniform admixture of:
(i) an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure: 22or wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; and (ii) a hydroxypropyl cellulose.
- 39. The composition of claim 38, wherein the active ingredient comprises a compound having the structure:
- 40. The composition of claim 38, wherein the active ingredient comprises valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium or valpromide.
- 41. A tablet comprising the granulate of claim 38 as a component.
- 42. The tablet of claim 41, wherein the granulate further comprises a filler.
- 43. The tablet of claim 41, further comprising a hydroxypropylmethyl cellulose as a component.
- 44. The tablet of claim 41, further comprising as additional components a filler, a lubricant and a flow agent.
- 45. The tablet of claim 43, further comprising as additional components a filler, a lubricant and a flow agent.
- 46. The tablet of claim 43, further comprising a different hydroxypropylmethyl cellulose as a component.
- 47. The tablet of claim 43, wherein
the hydroxypropylmethyl cellulose has 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve.
- 48. The tablet of claim 47, wherein at least 90% of the hydroxypropylmethyl cellulose passes through a No. 100 US standard sieve.
- 49. The tablet of claim 47, wherein
the hydroxypropylmethyl cellulose has an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cp) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.
- 50. The tablet of claim 46, wherein
the different hydroxypropylmethyl cellulose has 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve.
- 51. The tablet of claim 50, wherein at least 90% of the hydroxypropylmethyl cellulose passes through a No. 100 US standard sieve.
- 52. The tablet of claim 50, wherein
the different hydroxypropylmethyl cellulose has an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.
- 53. The tablet of claim 42, wherein the filler in the granulate is a microcrystalline cellulose.
- 54. The tablet of claim 45, wherein
the filler comprises a microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing; the lubricant comprises magnesium stearate, sodium stearyl fumarate or a combination thereof; and the flow agent comprises a colloidal fumed silica.
- 55. A sustained release tablet comprising a compound having the structure:
- 56. The sustained release tablet of claim 55, wherein the compound is N-(2-propylpentanoyl)glycinamide.
- 57. A method of treating neuropathic pain in a subject in need of such treatment comprising administering to the subject a therapeutically effective dose of the solid dosage form of any one of claims 1-28 or the tablet of any one of claims 29-37 or 41-56 in order to thereby treat the neuropathic pain in the subject.
- 58. A method of treating a headache disorder in a subject in need of such treatment comprising administering to the subject a therapeutically effective dose of the solid dosage form of any one of claims 1-28 or the tablet of any one of claims 29-37 or 41-56 in order to thereby treat the headache disorder in the subject.
- 59. A method of treating epilepsy in a subject in need of such treatment comprising administering to the subject a therapeutically effective dose of the solid dosage form of any one of claims 1-28 or the tablet of any one of claims 29-37 or 41-56 in order to thereby treat epilepsy in the subject.
- 60. A method of controlling seizures in a subject suffering from epilepsy comprising administering to the subject a therapeutically effective dose of the solid dosage form of any one of claims 1-28 or the tablet of any one of claims 29-37 or 41-56 in order to thereby control the seizures in the subject.
- 61. A method of treating pain in a subject in need of such treatment comprising administering to the subject a therapeutically effective dose of the solid dosage form of any one of claims 1-28 or the tablet of any one of claims 29-37 or 41-56 in order to thereby treat pain in the subject.
- 62. A method of pain prophylaxis in a subject in need of such treatment comprising administering to the subject a prophylactic dose of the solid dosage form of any one of claims 1-28 or the tablet of any one of claims 29-37 or 41-56 in order to thereby effect pain prophylaxis in the subject.
- 63. A method of treating mania in bipolar disorder in a subject in need of such treatment comprising administering to the subject a therapeutically effective dose of the solid dosage form of any one of claims 1-28 or the tablet of any one of claims 29-37 or 41-56 in order to thereby treat mania in bipolar disorder in the subject.
- 64. A method of attenuating bipolar mood swings in a subject suffering from bipolar disorder comprising administering to the subject a therapeutically effective dose of the solid dosage form of any one of claims 1-28 or the tablet of any one of claims 29-37 or 41-56 in order to thereby attenuate the bipolar mood swings in the subject.
- 65. A process for preparing the solid dosage form of claim 1 or 2, comprising the steps of:
a) admixing predetermined amounts of
(i) an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure: 25 wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; and (ii) a binder; b) admixing the uniform mixture of step a) with a predetermined amount of a hydroxypropylmethyl cellulose; and c) compressing the mixture of step b) to form the tablet.
- 66. The process of claim 65, wherein step b) further comprises admixing the uniform mixture with a predetermined amount of a different hydroxypropylmethyl cellulose.
- 67. The process of claim 66, wherein step b) further comprises admixing the uniform mixture with predetermined amounts of a filler, a lubricant and a flow agent.
- 68. The process of claim 67, wherein the flow agent comprises colloidal fumed silica.
- 69. The process of claim 67, wherein the filler comprises microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing.
- 70. The process of claim 69, wherein the filler comprises lactose.
- 71. The process of claim 67, wherein the lubricant comprises magnesium stearate or sodium stearyl fumarate or a combination thereof.
- 72. The process of claim 71, wherein the lubricant comprises magnesium stearate.
- 73. The process of claim 66, wherein
each hydroxypropylmethyl cellulose of step b) has 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve.
- 74. The process of claim 73, wherein at least 90% of the hydroxypropylmethyl cellulose passes through a No. 100 US standard sieve.
- 75. The process of claim 73, wherein
the first hydroxypropylmethyl cellulose has an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; and the second hydroxypropylmethyl cellulose has an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.
- 76. A process for preparing the hard compressed tablet of claim 29 comprising the steps of:
a) admixing predetermined amounts of N-(2-Propylpentanoyl)glycinamide, hydroxypropylmethyl cellulose, and a different hydroxypropylmethyl cellulose; and b) compressing the mixture of step a) to form the hard compressed tablet.
- 77. The process of claim 76, wherein
each hydroxypropylmethyl cellulose of step a) has 19%-24% by weight methoxyl substituent, 7%-12% by weight hydroxylproproxyl substituent and has a particle size distribution such that at least 99% of the hydroxypropylmethyl cellulose passes through a No. 40 US standard sieve.
- 78. The process of claim 77, wherein at least 90% of the hydroxypropylmethyl cellulose passes through a No. 100 US standard sieve.
- 79. The process of claim 77, wherein
the hydroxypropylmethyl cellulose has an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; and the different hydroxypropylmethyl cellulose has an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C.
- 80. The process of claim 76, wherein step a) further comprises admixing predetermined amounts of a filler, lubricant and flow agent as additional components.
- 81. The process of claim 80, wherein
the filler comprises microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing; the lubricant comprises sodium stearyl fumarate; and the flow agent comprises colloidal fumed silica.
- 82. A process for preparing the composition in granulate form of claim 38, comprising granulating a predetermined amount of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide or a compound having the structure:
- 83. A process for preparing a sustained release tablet comprising the steps of:
a) admixing the granules of claim 38 with predetermined amounts of a hydroxypropylmethyl cellulose; and b) compressing the mixture of step a) to form the tablet.
- 84. The process of claim 83, wherein step a) further comprises admixing the granules with a predetermined amount of each of a different hydroxypropylmethyl cellulose, a filler, a lubricant and a flow agent.
- 85. The process of claim 84, wherein the flow agent comprises colloidal fumed silica.
- 86. The process of claim 84, wherein the filler comprises microcrystalline cellulose, anhydrous dicalcium phosphate, lactose or a combination of two or more of the foregoing.
- 87. The process of claim 86, wherein the filler is lactose.
- 88. The process of claim 84, wherein the lubricant comprises magnesium stearate or sodium stearyl fumarate or a combination thereof.
- 89. The process of claim 88, wherein the lubricant comprises magnesium stearate.
- 90. The process of claim 83, comprising the steps of:
a) admixing the granules with predetermined amounts of hydroxypropyl methyl cellulose having an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C., and hydroxypropyl methyl cellulose having an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C.; and b) compressing the mixture of step a) to form the tablet.
- 91. The process of claim 90, wherein step a) further comprises admixing the granules with predetermined amounts of a flow agent, a filler, and a lubricant.
- 92. The process of claim 91 comprising the steps of
a) admixing the granules with
a predetermined amount of hydroxypropylmethyl cellulose with an apparent viscosity of 78-117 millipascal-seconds (nominal value 98 mPa.s) by rotation and 80-120 cP (nominal value 100 cP) by Ubbelhode, at a concentration of 1% by weight in water at 20° C. which results in tablets containing 150 mg/tablet; a predetermined amount of hydroxypropyl methyl cellulose with an apparent viscosity of 6,138-9,030 millipascal-seconds (nominal value 7382 mPa.s) by rotation and 11,250-21,000 cP (nominal value 15,000 cP) by Ubbelhode at a concentration of 1% by weight in water at 20° C. which results in tablets containing 60 mg/tablet; a predetermined amount of lactose which results in tablets containing 20 mg/tablet; a predetermined amount of magnesium stearate which results in tablets containing 4.5 mg/tablet; and a predetermined amount of a colloidal fumed silica which results in tablets containing 1 mg/tablet; and b) compressing the mixture of step a) to form the tablet.
- 93. Use of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure:
- 94. Use of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure:
- 95. Use of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure:
- 96. Use of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure:
- 97. Use of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure:
- 98. Use of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure:
- 99. Use of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure:
- 100. Use of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure:
- 101. The sustained release solid dosage form of any one of claims 1-28 or tablet of any one of claims 29-37 or 41-56 for use in treating a headache disorder in a subject.
- 102. The sustained release solid dosage form of any one of claims 1-28 or tablet of any one of claims 29-37 or 41-56 for use in treating neuropathic pain in a subject.
- 103. The sustained release solid dosage form of any one of claims 1-28 or tablet of any one of claims 29-37 or 41-56 for use in treating epilepsy in a subject.
- 104. The sustained release solid dosage form of any one of claims 1-28 or tablet of any one of claims 29-37 or 41-56 for use in controlling seizures in a subject suffering from epilepsy.
- 105. The sustained release solid dosage form of any one of claims 1-28 or tablet of any one of claims 29-37 or 41-56 for use in treating mania in bipolar disorder in a subject.
- 105. The sustained release solid dosage form of any one of claims 1-28 or tablet of any one of claims 29-37 or 41-56 for use in attenuating bipolar mood swings in a subject suffering from bipolar disorder.
- 106. The sustained release solid dosage form of any one of claims 1-28 or tablet of any one of claims 29-37 or 41-56 for use in treating pain in a subject.
- 107. The sustained release solid dosage form of any one of claims 1-28 or tablet of any one of claims 29-37 or 41-56 for use in effecting pain prophylaxis in a subject.
- 108. A controlled release oral unit dose composition comprising N-(2-propylpentanoyl)glycinamide and at least one pharmaceutically acceptable carrier, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycinamide between 4 and 24 hours after ingestion of a single oral unit dose.
- 109. The controlled release oral unit dose composition of claim 108, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycinamide between 4 and 12 hours after ingestion of a single oral unit dose.
- 110. The controlled release oral unit dose composition of claim 109, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycinamide between 6 and 12 hours after ingestion of a single oral unit dose.
- 111. The controlled release oral unit dose composition of claim 110, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycinamide between 6 and 8 hours after ingestion of a single oral unit dose.
- 112. The controlled release oral dose composition of any one of claims 108 to 111, wherein the peak blood plasma level of N-(2-propylpentanoyl)glycinamide is from 0.5 micrograms/ml to 16 micrograms/ml per a 1000 mg dose of N-(2-propylpentanoyl)glycinamide in the composition.
- 113. The controlled release oral dose composition of claim 108, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycine in the human subject from 0.5 μg/mL to 1.7 μg/mL per a 1000 mg dose of N-(2-propylpentanoyl)glycinamide in the composition.
- 114. A controlled release oral dose composition comprising N-(2-propylpentanoyl)glycinamide and a pharmaceutically acceptable carrier, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycinamide of 0.5 μg/mL to 16 μg/mL per a 1000 mg dose in the composition.
- 115. A controlled release oral dose composition comprising N-(2-propylpentanoyl)glycinamide and a pharmaceutically acceptable carrier, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycine of 0.5 μg/mL to 1.7 μg/mL per a 1000 mg dose of N-(2-propylpentanoyl) glycinamide in the composition.
- 116. A method of inducing in a human subject a peak blood plasma level of N-(2-propylpentanoyl)glycinamide between 4 and 24 hours after administration of N-(2-propylpentanoyl)glycinamide, comprising administering to the human subject a controlled release oral unit dose composition comprising N-(2-propylpentanoyl)glycinamide and at least one pharmaceutically acceptable carrier, which composition induces a peak blood plasma level of N-(2-propylpentanoyl)glycinamide between 4 and 24 hours after administration of a single oral unit dose.
- 117. The method of claim 116, wherein the peak blood plasma level of N-(2-propylpentanoyl)glycinamide occurs between 4 and 12 hours after administration.
- 118. The method of claim 116, wherein the peak blood plasma level of N-(2-propylpentanoyl)glycinamide is 0.5 μg/mL to 16 μg/mL per 1000 mg dose of N-(2-propylpentanoyl)glycinamide in the composition.
- 119. The method of any one of claims 116-118, wherein the administration to the human subject of a controlled release oral unit dose composition comprising N-(2-propylpentanoyl)glycinamide and at least one pharmaceutically acceptable carrier induces a peak blood plasma level of N-(2-propylpentanoyl)glycine in the human subject from 0.5 μg/mL to 1.7 μg/mL upon administration of a single 1000 mg dose of N-(2-propylpentanoyl)glycinamide.
- 120. The method of any one of claims 116-119, wherein the controlled release oral dose composition is the solid dosage form of any one of claims 18-28 or the tablet of any one of claims 29-37 or 41-56.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application No. 60/445,328, the entire contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60445328 |
Feb 2003 |
US |